Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group study

Cancer

Volumn 88, Issue 5, 2000, Pages 1159-1165

  Williamson, Stephen K ^a,f   Lew, Danika ^b,f   Miller, Gary J ^c,f   Balcerzak, Stanley P ^d,f   Baker, Laurence H ^e,f   Crawford, E David ^c,f  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f Southwest Oncology Group   (United States)

Author keywords

Adrenal carcinoma; Chemotherapy; Cisplatin; Etoposide; Medical oncology

Indexed keywords

CISPLATIN; CORTISONE ACETATE; ETOPOSIDE; FLUDROCORTISONE ACETATE; MITOTANE;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LETHARGY; MALAISE; MALE; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTANE;

EID: 0034162574     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R     Document Type: Article

References (25)

1. Richie JP, Gittes RF. Carcinoma of the adrenal cortex. Cancer 1980;45(7 Suppl):1957-64.
2. Hutter AM Jr., Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med 1966;41(4):581-92.
3. Hutter AM Jr., Kayhoe DE. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 1966;41(4):572-80.
4. Macfarlane D. Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1985;23:155-86.
5. May C, Gamett W. Treatment of adrenocortical carcinoma: a case report and review of the literature. Drug Intelligence Clin Pharmacol 1986;20:24-32.
6. Harinarayan CV, Gupta S, Ammini AC, Karmarkar MG, Gupta R, Sharma LK, et al. Clinical utility of ketoconazole in cases of adrenocortical carcinoma. Indian J Cancer 1991; 28(4):196-201.
7. Berganstal D, Hertz R, Lipsett MB, Moy RH. Chemotherapy of adrenocortical cancer with O,P'-DDD. Ann Intern Med 1960;53:672-82.
8. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973;223(10):1109-12.
9. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy [see comments]. N Engl J Med 1990;322(17):1195-201.
10. Haq MM, Legha SS, Samaan NA, Bodey GP, Burgess MA. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 1980;64(8-9):909-13.
11. Hajjar RA, Mickey RC, Samaan NA. Adrenal cortical carcinoma. A study of 32 patients. Cancer 1975;35(2):549-54.
12. King DR, Lack EE. Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer 1979;44(1):239-44.
13. Nader S, Hickey RC, Sellin RV, Samaan NA. Adrenal cortical carcinoma. A study of 77 cases. Cancer 1983;52(4):707-11.
14. Chun HG, Yagoda A, Kemeny N, Watson RC. Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep 1983;67(5): 513-4.
15. van Slooten H, van Oosterom AT. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983;67(4):377-9.
16. Schabet FM Jr., Trader MW, Laster WR Jr., Corbett TH, Griswold DP Jr. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979;63(9-10):1459-73.
17. Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986;58(10):2198-202.
18. Hesketh PJ, McCaffrey RP, Finkel HE, Larmon SS, Griffing GT, Melby JC. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 1987;71(2):222-4.
19. Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993;11(1):161-5.
20. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992;112(6):981-6.
21. Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991;73(1):18-29.
22. Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 1998;78(4):546-9.
23. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998;83(10): 2194-200.
24. Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991;110(6): 1006-13.
25. Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134(2):181-5.